推荐进行侵袭性心脏干预治疗ST段抬高型心肌梗死、非ST段抬高型急性冠状动脉综合征、多血管冠状动脉疾病、严重症状性主动脉狭窄和心肌病。这些推荐是基于随机对照试验，但这些试验历史上包含的有活跃的进展性恶性肿瘤的个体较少。进展性恶性肿瘤对死亡率构成重要的竞争风险，对于这类患者进行侵袭性心脏干预治疗的风险和利益的证据有限。我们回顾了侵袭性心脏干预治疗的益处；围手术期的考虑因素；对多种活跃的进展性恶性肿瘤患者的当代存活预期；以及这些人群心血管干预治疗的文献。我们的目标是制定一个合理的框架，以指导在有活跃的进展性癌症患者中使用侵袭性心脏干预治疗的临床推荐。©2023作者们

Invasive cardiac interventions are recommended to treat ST-segment elevation myocardial infarction, non-ST-segment elevation acute coronary syndromes, multivessel coronary disease, severe symptomatic aortic stenosis, and cardiomyopathy. These recommendations are based on randomized controlled trials that historically included few individuals with active, advanced malignancies. Advanced malignancies represent a significant competing risk for mortality, and there is limited evidence to inform the risks and benefits of invasive cardiac interventions in affected patients. We review the benefit conferred by invasive cardiac interventions; the periprocedural considerations; the contemporary survival expectations of patients across several types of active, advanced malignancy; and the literature on cardiovascular interventions in these populations. Our objective is to develop a rational framework to guide clinical recommendations on the use of invasive cardiac interventions in patients with active, advanced cancer.© 2023 The Authors.